RSS

Merck Inaugurates Biomass Plant in Goa, India

  • Co-generation unit promotes climate protection and energy efficiency
  • To manufacture vitamin preparations, industrial and laboratory chemicals as well as microbiological products, among others

Goa/Mumbai, November 25, 2014 – Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, today commissioned a climate-neutral co-generation plant at its production site in Goa, India.

Goa

In doing so, Merck is underscoring its commitment to climate protection and energy efficiency in line with its corporate responsibility. The project is part of a company-wide climate protection program. Merck previously commissioned a new co-generation plant at its headquarters in Darmstadt in July.

Thierry Hulot

Dr. Thierry Hulot, Executive Vice President, Head of Global Manufacturing & Supply
and Member of Merck Pharmaceutical Executive Committee

Dr. Thierry Hulot, Executive Vice President, Head of Global Manufacturing & Supply and Member of Merck Pharmaceutical Executive Committee visited India on the occasion and inaugurated the plant. He said, “Merck’s new climate-neutral co-generation plant in Goa has a tremendous power output for our pharmaceutical and chemical production operations. In the manufacture of our products, we seek to impact the environment as little as possible. As a responsible company, we express our respect to the environment in an Industrial Plant that provides medicines for millions of patients in India.”

Merck’s Goa site is located in Usgao, around 45 kilometers from Panaji, the capital of the Indian state of Goa. This co-generation unit, which has a power output of three megawatts, generates electricity and steam for the pharmaceutical and chemical production operations in Goa. Merck is mainly recycling the shells of cashews and coconuts, two crops that are farmed in the region, to use as biomass. Overall, this will make it possible to reduce carbon dioxide emissions by around 11,500 metrics tons, corresponding to around 85% of the site’s total CO2 emissions. The biomass plant, which represents an investment of more than € 3 million, will ensure that the site has a reliable supply of energy and can operate independently of the public power grid. More than 300 employees manufacture vitamin preparations, industrial and laboratory chemicals as well as microbiological products, among other things.

Mr. Pramod Pimplikar, Director - Technical Operations, GMS- Merck Serono

Mr. Pramod Pimplikar, Director – Technical Operations, GMS- Merck Serono

Speaking on the occasion, Mr. Pramod Pimplikar, Director – Technical Operations, GMS- Merck Serono said, “We are extremely excited in being able to make a positive difference to our business, the environment and capacity building efforts. With this Green field site, we aim to reduce CO2 emission by 85% and deliver clean, green, efficient, reliable power and steam supply, improving efficiencies and contributing to the nation’s interest. By 2020 Merck KGaA has committed to reduce its global CO2 emissions by 20% and we are happy to be in a position to contribute to those efforts.”

The climate protection program Edison comprises around 300 climate protection and energy efficiency activities of the Merck Group. The objective is to reduce greenhouse gas emissions from energy generation as well as to enhance the energy efficiency of research and production processes. Merck aims to reduce its total direct and indirect greenhouse gas emissions by 20% by 2020, measured against the 2006 baseline. At its site in Jaffrey, New Hampshire (USA), Merck plans to commission a further biomass central heating plan next year.

Merck Groa Biomass Plant - Key Benefits

Merck is a leading company for innovative, top-quality high-tech products in the chemical, pharmaceutical and life science sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of around € 11.1 billion in 2013. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of customers, and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

 
 

Tags: , , , , , , , , , , ,

Merck Advances to Sixth Place in the 2014 Access to Medicine Index

  • Merck moves up two places from previous rank 8
  • Access to Medicine Foundation acknowledges Merck’s strategic approach to access to health

Darmstadt, Germany, November 18, 2014 – Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, announced today that it now ranks sixth in the Access to Medicine Index published yesterday by the Access to Medicine Foundation. Merck has moved up two places compared to the 2012 ranking. This improvement underlines the company’s commitment to helping overcome barriers to access for underserved populations and communities in low- and middle-income countries as part of its corporate responsibility and sustainable business approach. Every two years, the Access to Medicine Index benchmarks the top pharmaceutical companies on activities and initiatives that are advancing access to medicines in developing countries.

A2H_Praziquantel

“Merck has revised its Access to Health strategy and has launched new initiatives since 2012 including a pro-access business model in India and an innovative initiative to increase local manufacturing capabilities,” the Access to Medicine Foundation cited as reasons why Merck has advanced in the new ranking.

“Our efforts have been well-recognized by the Access to Medicine Foundation and we are proud to be ranked among the top leading companies only three years after starting our Access to Health initiative,” Stefan Oschmann, Chief Executive Officer Pharma and Vice Chairman Elect of the Executive Board of Merck, said. ”The fact that we’ve once again improved our ranking proves that access to health has become an integral part of how we conduct business. Of course we will continue our endeavors to better help patients, who are at the core of all our efforts, and to possibly further contribute to alleviating the various barriers to access for those most in need.”

Merck’s strategy to addressing the complex challenge of providing access to underserved populations and patients in low- and middle-income countries focuses upon four priority areas, known as the 4As for Availability, Affordability, Awareness and Accessibility. Whereas availability includes refining of health solutions to address unmet needs tailored to local environments, affordability entails addressing the inability to pay challenge. Awareness focuses on empowering people with appropriate tools and knowledge to make informed decisions, whether through education and training or metrics and evidence gathering, and accessibility comprises initiatives to strengthen supply chain and develop localized health solutions.

Compared to 2012, Merck now has been recognized by the Access to Medicine Foundation in particular for leading practices such as:

  • Strategic approach that comprises for example a strong focus on research & development for local and unmet needs and innovative manufacturing and distribution initiatives, including forward integration of supply chains
  • Multi-dimensional approach to fight the tropical worm disease schistosomiasis: a long-term donation program that aims to help eliminate the disease, as well as the development of a new diagnostic tool and a pediatric formulation
  • Pro-access IP management comprising of a commitment not to file for or enforce patents in the widest range of developing countries, access policies for future on-patent products, and open innovation initiatives
  • Merck established its Access to Health initiative in February 2011 and has identified access gaps and opportunities to better meet the needs of underserved patients. The unit is ensuring that access brings added value to the community at large, and is becoming an integral part of how Merck conducts business in a responsible, sustainable manner. Merck launched the Su-Swastha pilot program, a pro-access business model aiming at increasing access to healthcare products at an affordable price in rural India. Another example is the Merck Capacity Advancement Program (CAP) to raise awareness of diabetes in Africa and in India by educating the public and supporting the healthcare system on ways to prevent, diagnose and manage diabetes effectively. In summary, Merck recognizes the complexity of bringing health solutions to the poor and understands that Access to Medicine Index objectives cannot be reached by the pharmaceutical industry alone. Partnership, collaboration and continuous dialogue with a diverse array of stakeholders are key to ensuring that the delivery of sustainable access solutions is serving people’s needs.

Access to Medicine Foundation
The Access to Medicine Foundation is an international not for profit organization stimulating pharmaceutical companies to improve access to medicine to societies in need. Based in Haarlem, the Netherlands, the Foundation publishes the Access to Medicine Index, the first Index of its kind to rank pharmaceutical companies with respect to their efforts to enhance global access to medicine.

The Foundation aims to advance access to medicine in developing countries by encouraging the pharmaceutical industry to accept a greater role towards improving access to medicine in less developed countries. Please find more information here.

Access to Medicine Index
Access to medicines remains a very serious concern for billions of people suffering from disease and is still a primary challenge for the global health system. Reflecting the key role of the pharmaceutical industry in addressing the challenges of access, it is essential that the Access to Medicine Index’s approach to monitoring and evaluating the performance of the industry in this work is robust, balanced and comprehensive. The foundation every two years ranks 20 medium to large-size pharmaceutical companies with respect to their efforts to enhance global access to medicine. You can see the latest ranking as well as rankings from the past here.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors. With its four divisions Merck Millipore, Merck Serono, Performance Materials and Consumer Health, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as Merck KGaA, Darmstadt, Germany.

 
Leave a comment

Posted by on November 19, 2014 in Merck Serono, Wellness

 

Tags: , ,

Merck Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

  • Merck and Pfizer will jointly develop and commercialize Merck’s anti-PD-L1
  • Joint investment and combined strengths and capabilities will further maximize potential of Merck’s asset in the highly competitive anti-PD-1 / anti-PD-L1 space
  • Up to 20 high priority immuno-oncology clinical development programs expected to commence in 2015, including pivotal registration studies
  • Alliance accelerates Merck’s entry into the US oncology market

Darmstadt, Germany, November 17, 2014 – Merck (MRK GY) announced today that it has entered into a global agreement with Pfizer Inc. (NYSE:PFE) to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

The asset will be developed as a single agent as well as in various combinations with Pfizer’s and Merck’s broad portfolio of approved and investigational pipeline candidates. The two companies will also combine resources and expertise to advance Pfizer’s anti-PD-1 antibody into Phase 1 trials. As part of the agreement, Merck will co-promote Pfizer’s XALKORI, a medicine to treat non-small cell lung cancer, in the United States and several other key markets.

e629723f-4073-4367-8e1f-66f6826f84e3-medium

Karl-Ludwig Kley, Chairman of Merck’s Executive Board stated: “We live up to our promise to strengthen all three pillars of our business: Healthcare, Performance Materials and Life Science. After this year’s acquisition of AZ Electronic Materials and the proposal to acquire Sigma-Aldrich, we have now turned the focus on healthcare. The agreement with Pfizer is a very important milestone in taking our pharma pipeline forward.”

“Collaborating globally with Pfizer will allow us to benefit from the strengths and capabilities of both companies in immuno-oncology, further accelerating this promising asset in the race to address the needs of cancer patients across multiple tumor types. Up to 20 high priority immuno-oncology clinical development programs are expected to commence in 2015, including pivotal registration studies,” continued Belén Garijo, President and Chief Executive Officer of Merck’s biopharmaceutical division Merck Serono and Executive Board Member Elect. “On top of that, the global alliance will enable Merck to gain an early entry into the US oncology market as well as to strengthen our existing oncology business in several other important global markets.”

There are currently two clinical development programs underway evaluating Merck’s anti-PD-L1 antibody. In a Phase 1 trial, more than 550 patients have been treated with MSB0010718C across multiple types of cancers. As part of the Analyst and Investor Day hosted by Merck on September 18, 2014, interim data were presented from the ongoing Phase 1 study demonstrating a complete response and partial responses in patients with non-small cell lung cancer and ovarian cancer. Additional data are expected to be presented at medical congresses in 2015. There is also an ongoing Phase 2 trial evaluating this antibody in patients with m-Merkel cell carcinoma, a rare form of skin cancer. For more information, please visit http://www.clinicaltrials.gov

Under the terms of the agreement, Merck will receive an upfront payment of $ 850 million (around € 680 million) and is eligible to receive regulatory and commercial milestone payments up to $ 2.0 billion. Both companies will jointly fund all development and commercialization costs and all revenues obtained from selling any anti-PD-L1 or anti-PD-1 products generated from this collaboration will be shared.

“Our strategic focus in the immuno-oncology space will be significantly enhanced through this global alliance, giving us the financial firepower to fully leverage the potential of our anti-PD-L1-compound” said Stefan Oschmann, Chief Executive Officer Pharma and Vice Chairman Elect of the Executive Board of Merck. “The success of the anti-PD-L1 program and the value recognised by Pfizer is a clear reflection of the progress we have made on our R&D pipeline in recent years.”

“This global alliance enables Pfizer and Merck to join forces and combine complementary strengths with the goal of meeting the needs of patients with multiple types of cancer,” said Albert Bourla, Group President Vaccines, Oncology and Consumer Healthcare Businesses, Pfizer. “Immuno-oncology is a top priority for Pfizer. Combining this promising anti-PD-L1 antibody with Pfizer’s extensive portfolio of small molecules and antibodies provides an opportunity to potentially broaden the use of immunotherapy for patients with cancer and rapidly expand our oncology business. In addition, this alliance enables us to significantly accelerate the time-frame of our development programs and move into the first wave of potential immuno-oncology based treatment regimens.”

All Merck news releases are distributed by e-mail at the same time they become available on the Merck website. Please go to http://www.merckgroup.com/newsabo to register online, change your selection or discontinue this service.
Merck is a leading company for innovative, top-quality high-tech products in the chemical and pharmaceutical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of around € 11.1 billion in 2013. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of customers, and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

Cautionary Note Regarding Forward-Looking Statements
Certain statements made herein may be deemed to be solicitation materials in respect of the proposed acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany. The proposed acquisition will be submitted to the stockholders of Sigma-Aldrich for their consideration on December 5, 2014. In connection therewith, on November 3, 2014, Sigma-Aldrich filed a definitive proxy statement with the SECand began mailing the definitive proxy statement to its stockholders of record as of the close of business on October 29, 2014. BEFORE MAKING ANY VOTING OR ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders may obtain free copies of the proxy statement, any amendments or supplements thereto and other documents containing important information about Sigma-Aldrich, once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Sigma-Aldrich will be available free of charge on Sigma-Aldrich’s website at http://investor.sigmaaldrich.com under the heading “Financial Information—SEC Filings”. Stockholders of Sigma-Aldrich may also obtain a free copy of the definitive proxy statement by contacting Sigma-Aldrich’s Investor Relations Department at (314) 898-4643.

Sigma-Aldrich and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Sigma-Aldrich is set forth in its proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on March 21, 2014, its annual report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on February 6, 2014, and in subsequent documents filed with the SEC, each of which can be obtained free of charge from the sources indicated above. Other information regarding the participants in the proxy solicitation of the stockholders of Sigma-Aldrich and a description of their direct and indirect interests, by share holdings or otherwise, is contained in the definitive proxy statement and other relevant materials filed with the SEC.

 
Leave a comment

Posted by on November 17, 2014 in Merck Serono

 

Tags: , , , , , , ,

Merck reports strong top-line growth in the 3rd Quarter 2014

1922309_881914215154739_3719811746879264206_nNovember 13, 2014 – Merck delivered strong sales growth of 9.3%, reporting sales of € 2.9 billion in the third quarter of 2014 (Q3 2013: € 2.7 billion). Owing to the good business performance in the first nine months and the very good organic sales growth in the third quarter, Merck is assuming slight organic sales growth for the full year 2014.

  • Sales increase by 9.3% in Q3
  • All regions on a growth course, Emerging Markets fuel growth further
  • EBITDA pre one-time items increases by 3.1% to € 857 million
  • Merck raises sales guidance and reiterates forecast for EBITDA pre one-time items for the full year 2014

 

 
Leave a comment

Posted by on November 13, 2014 in Industry, Merck Serono

 

Tags: , , , , , , ,

Merck Lends Support in the Fight Against Ebola

• Donation of € 250,000 made to the German Red Cross

Darmstadt, Germany, October 31, 2014 – Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, will be donating € 250,000 to support the German Red Cross, a member of the International Federation of Red Cross and Red Crescent Societies, in the fight against Ebola. With this donation, the company is underlining social responsibility as part of its entrepreneurial approach.

ebola-virus-back-again134

“We want to help the people who are suffering in the affected countries quickly and in an uncomplicated manner. Therefore, we are providing the German Red Cross with € 250,000,” said Stefan Oschmann, CEO Pharma and Member of the Executive Board of Merck. “Our donation complements the many different initiatives with which Merck is helping to improve access to medicines and medical care for the people of Africa,” Oschmann added. The fight against the tropical worm disease schistosomiasis through donations of praziquantel tablets to the World Health Organization as well as efforts to contain the spread of counterfeit medicines through the use of mobile Minilabs represent two initiatives by Merck in this area.

“The entire provision of health care in Sierra Leone, Liberia and Guinea has virtually fallen apart. The conditions prevailing locally are catastrophic. We are therefore very happy to receive Merck’s contribution to the fight against Ebola,” said Rudolf Seiters, President of the German Red Cross. Local Red Cross aid workers have been in action since the outbreak of the epidemic in West Africa. The German Red Cross is supporting the national Red Cross organizations. In addition, the German Red Cross is expanding and enhancing a treatment center for Ebola patients operated by the International Red Cross in Sierra Leone. In Liberia, the German Red Cross will begin operating a treatment center for Ebola patients, with support from the German military, as of mid-November.

More information on the fight against Ebola can be found on the website of the International Federation of Red Cross and Red Crescent Societies.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of our customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

 
Leave a comment

Posted by on November 13, 2014 in Merck Serono

 

Tags: , , , , , ,

Allergopharma and S-TARget Therapeutics Conclude Licensing Agreement

Objective is a new generation of therapeutics for allergy treatment

Allergopharma

Reinbek, Germany, September 2, 2014 – Allergopharma, the Merck Business Unit Allergy, and S-TARget therapeutics (S-TARget), an Austrian biotechnology company which develops therapeutic preparations for all forms of allergies, have signed an exclusive licensing agreement. The main focus of this cooperation is the use of S-TARget S-TIR™ technology and the associated development of a new generation of products for the causal treatment of allergies. The parties have agreed on confidentiality regarding the general terms and financial details of the transaction.
“We are pleased to have gained S-TARget as a partner. For Allergopharma, this is an important building block for our innovation-oriented strategy,” said Marco Linari, CEO Allergopharma/Merck Business Unit Allergy. “With S-TARget’s technology platform, we have great potential available to develop new therapeutic forms for the most significant allergens, such as dust mites and pollen. We will now be working very hard on the further development of the active ingredients based on the licensed technology platform. Our objective is to develop market-ready products as quickly as possible, so that we can better help patients suffering from allergies.”
stargetChristof Langer, CEO and co-founder of S-TARget, elaborated: “With strong positioning in the allergy sector, its close connections to the medical field and expertise in highly modern technologies for the development and manufacture of allergy preparations, Allergopharma is an excellent match for us. This cooperation gives us both the opportunity to advance the development of our innovative technology and bring new therapies onto the market.”
With the signing of the agreement, Allergopharma, one of the leading manufacturers of therapeutics for specific immunotherapy for type 1 allergies like hay fever or allergic asthma, gains worldwide rights for the development and marketing of the envisaged products on the basis of S-TARget‘s S-TIRTM technology platform. Through this partnership, Allergopharma is investing more heavily in research, with the objective of developing a new generation of products for specific allergy therapeutics. Merck is continuing to invest in the highly attractive therapeutic area of allergies and is focused on innovation and the next generation of allergy therapy.
The market for allergy therapeutics (without symptomatic drugs) is a global growth market, in which Allergopharma is already one of today’s market leaders. The worldwide growth expected by market observers is, on one hand, due to the increasing number of allergy sufferers and, on the other hand, is based on the increasing prevalence of specific immunotherapy in many emerging economies.

Merck Subsidiary

Allergopharma
Allergopharma was founded in 1969 by Hermal and Joachim Ganzer in Reinbek, Hamburg. More than 480 employees work there today, of which more than 60 work in R&D.
Since 2013 Allergopharma has been fully integrated into Merck as the Business Unit Allergy. The managing director is Dr. Marco Linari. With the competency of a company operating on a global scale, Merck is striving in particular towards international expansion, strengthening business in Europe and the development of future products in the allergy business sector and intends make significant investments in this market segment.
The success of Allergopharma is mainly based on the hypoallergenic, high-dose preparations (allergoids), which can be used pre-seasonally or throughout the year. Some major advantages of the subcutaneous specific immunotherapy (SCIT) predominantly offered by Allergopharma is a close physician/patient relationship, good patient compliance and high degree of efficacy, as well as a positive cost-benefit ratio. Allergopharma is the global market leader in this area.
Specific immune therapy (SIT) – also known as hyper-sensitization – is generally recognized as the only causal form of treatment for allergies, and can prevent the progression of an allergy to asthma, as well as the development of new sensitizations and further allergies.
Allergopharma has developed into one of the world’s leading research-driven pharmaceutical companies in the area of SIT with its claim to the highest quality standards in its work and the constant improvement in its products.
Allergopharma is also well-equipped for the future as the company already holds a leading position in the development of biotechnologically manufactured allergens, so-called recombinant allergens.

For more information, go to http://www.allergopharma.de

S-TARget therapeutics
S-TARget therapeutics is a biotechnology start-up, which has been operating from its location in Vienna, Austria since 2009. The active ingredients developed by S-TARget are based on a company-owned technology platform, S-TIRTM , which goes to the source of allergies, thereby not only relieving symptoms, but also aiding in the patient’s recovery. SG100, which targets house dust mite, is the company’s best-developed active ingredient. Since 2013 S-TARget has successfully expanded its Research & Development activities for S-TIRTM technology within the framework of a 100% spin-off to include clinical indications in oncology, auto-immune disease and infectious diseases.
S-TARget GmbH was founded in 2010 by immunologist Dr. Geert C. Mudde and biotechnologist Dr. Christof Langer, MBA. Both of the company’s founders have extensive experience in pharmaceutical research, as well as with managing internationally operating companies and start-ups. The development of S-TARget’s S-TIRTM technology was supported by a wide variety of national and international funders.
For more information on S-TARget, go to http://www.s-target.com

All Merck press releases are also sent by email simultaneously with their publication on the Internet: Use the web address http://www.merck.de/newsabo, to register online, to modify the choice made or to unsubscribe from the service.
Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemicals sectors. In 2013, Merck generated total revenues of approx. €11.1 billion with its four divisions, Merck Serono, Consumer Health, Performance Materials and Merck Millipore. Approximately 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of its customers and to make a contribution to the solution of global challenges. Merck is the world’s oldest pharmaceutical and chemical company, and has stood for innovation, commercial success and corporate responsibility since 1668. The founding family retains a majority ownership of the company of around 70% to this day. Merck is based in Darmstadt, and owns the global rights to the Merck name and brand. Canada and the USA are exceptions, where the company is known under the brand name EMD.

 
Leave a comment

Posted by on September 2, 2014 in Industry

 

Tags: , ,

Merck Reports Organic Growth in all Four Businesses in Second Quarter

  • Sales rise in the second quarter by 1.9%, AZ acquisition compensates for negative foreign exchange effects
  • EBITDA pre one-time items up 2.3% to € 846 million despite lower royalty, license and commission income; EBITDA pre margin improves to 30.3%
  • All businesses contribute to double-digit organic sales growth in Emerging Markets
  • Net income down -4.1% due to one-time effects of AZ inventory revaluation
  • Full-year forecast confirmed – despite negative foreign exchange effects and lower royalty, license and commission income

Darmstadt, Germany, August 13, 2014 – Merck, a leading company for top-quality high-tech products in the pharmaceutical and chemical sectors, generated organic sales growth of 3.4% in the second quarter of 2014. In addition, the company reported an acquisition-related sales increase of 3.0%, which was countered by negative foreign exchange effects of -4.5%. Overall, sales thus increased moderately by € 52 million or 1.9% to € 2.8 billion in the second quarter (Q2 2013: € 2.7 billion). Despite considerably lower royalty, license and commission income, EBITDA pre one-time items grew to € 846 million, equivalent to an EBITDA margin pre one-time items of 30.3% (Q2 2013: 30.1%).

“We had a solid second quarter,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck. “This was primarily due to our healthy operating business. Especially in Emerging Markets, all our divisions performed well. Merck’s stronger focus on this attractive region is visibly paying off. The completed acquisition of AZ is also having a positive effect on Group sales and EBITDA pre one-time items.”

Merck_4698Royalty, license and commission income fell sharply by -30.4% to € 68 million in the second quarter (Q2 2013: € 97 million). This was mainly due to the decline in royalty and license income in the Merck Serono division. Total revenues, in other words sales plus royalty, license and commission income, nevertheless increased by 0.8% to € 2.9 billion (Q2 2013: € 2.8 billion), reflecting the strength of the operating business.

The operating result (EBIT) of the Merck Group declined by € -24 million to € 441 million in the second quarter. This was largely attributable to the higher level of one-time items, especially from acquisitions, lower royalty, license and commission income, as well as negative foreign exchange effects in comparison with the year-ago period. The operating business and the efficiency improvement measures implemented within the scope of the “Fit for 2018″ transformation and growth program had a positive effect.

After adjusting for depreciation, amortization and one-time items, EBITDA pre one-time items, the key financial indicator used to steer operating business, grew by 2.3% to € 846 million (Q2 2013: € 826 million), resulting in an EBITDA margin pre one-time items relative to sales of 30.3% (Q2 2013: 30.1%). Taking into account the 1:2 share split, earnings per share pre one-time items amounted to € 1.16 in the second quarter of 2014 (Q2 2013: € 1.13).

Emerging Markets are a key driver of organic growth
From a regional perspective, dynamic business in Emerging Markets contributed first and foremost to the organic sales growth of the Merck Group. Very strong growth of 11.1% was mainly driven by the Merck Serono and Merck Millipore divisions. Including negative foreign exchange effects of -8.5% and increases of 5.9% from the AZ acquisition, Merck generated sales of € 1.0 billion in the Emerging Markets region (Q2 2013: € 967 million), equivalent to an increase of 8.5%. The Emerging Market region’s share of Group sales thus grew to 37% in the second quarter (Q2 2013: 35%), exceeding Europe (36%) despite stronger foreign exchange effects.

All four divisions of the Merck Group delivered organic sales growth in the second quarter. In particular, Consumer Health generated a good organic sales increase of € 15 million, equivalent to a growth rate of 8.5%. Delivering an absolute increase of € 44 million (3.0%), Merck Serono made the largest contribution to organic sales growth.

“At Merck Serono, we want to further expand our business with existing medicines this year. To this end, we are focusing on Emerging Markets with a high number of underserved patients. The past quarters have already confirmed the success of this approach,” said Kley.

For the Merck Serono division, slight organic sales growth over the previous year is assumed. It can be expected that the well-balanced product portfolio as well as organic growth in the Emerging Markets region will offset the declines in sales of Rebif resulting from the competitive situation in the United States and Europe. EBITDA pre one-time items of Merck Serono should decrease slightly in 2014 as forecast, particularly as a result of the expected decline in royalty, license and commission income, which will have a net effect of approximately € -100 million versus 2013. For the Consumer Health division, Merck forecasts moderate organic sales growth in 2014. Merck expects that all regions and especially the core strategic brands will contribute to sales growth. EBITDA pre one-time items should likewise increase moderately in 2014 as a result of positive sales developments. Merck assumes that the Performance Materials division will achieve slight organic sales growth in 2014. Overall, the acquisition of AZ Electronic Materials will lead to a substantial increase in the sales of the Performance Materials division despite negative foreign exchange effects. EBITDA pre one-time items of the division should therefore also increase considerably in 2014. The integration costs resulting from the acquisition of AZ Electronic Materials are estimated to amount to around € 50 million, approximately € 10 million of which will be incurred in 2014. For Merck Millipore, moderate organic sales growth is expected in 2014, which will however be partly offset by foreign exchange effects. Based on forecast sales growth, EBITDA pre one-time items should increase slightly in 2014.

For more detail report, please visit  http://www.merckgroup.com/company.merck.de/en/images/Q2_2014_Quarterly%20Report_final_EN_tcm1612_126074.pdf?Version=

 
Leave a comment

Posted by on August 14, 2014 in Industry

 
 
Follow

Get every new post delivered to your Inbox.

Join 64,875 other followers